Belantamab mafodotin

What Is Belantamab mafodotin?

• Belantamab mafodotin-blmf (Blenrep) is a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

What are the uses of this medicine?

Blenrep is a prescription medicine used to treat adults with multiple myeloma who:

• have received at least 4 prior medicines to treat multiple myeloma, and
• their cancer has come back or did not respond to prior treatment.

How does this medicine work?

• An antibody-drug conjugate (ADC) consisting of belantamab, an afucosylated, humanized monoclonal antibody, directed against the B-cell maturation antigen (BCMA), conjugated to mafodotin, an auristatin analogue and microtubule inhibitor monomethyl auristatin phenylalanine (MMAF), with potential antineoplastic activity.
• Upon administration of belantamab mafodotin, the anti-BCMA antibody moiety selectively binds to BCMA on tumor cell surfaces.
• Upon internalization, the MMAF moiety binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces tumor cell apoptosis.
• In addition, belantamab mafodotin induces antibody-dependent cellular cytotoxicity (ADCC).
• Altogether, this results in the inhibition of cellular proliferation in tumor cells that overexpress BCMA.
• BCMA, a receptor for a proliferation-inducing ligand and B-cell activating factor, is a member of the tumor necrosis factor (TNF) receptor superfamily and plays a key role in plasma cell survival; it is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.
• Afucosylation of the antibody moiety increases ADCC.

Who Should Not Use this medicine ?

• This medicine have no usage limitations

Is this medicine FDA approved?

• It was approved for use in the United States in 2020.

How should this medicine be used?

• The recommended dosage is 2.5 mg/kg as an intravenous infusion over approximately 30 minutes once every 3 weeks.
• Perform an ophthalmic exam prior to initiation of Blenrep and during treatment.

Administration

• Blenrep will be given to you by your healthcare provider by intravenous infusion into your vein over approximately 30 minutes.
• Blenrep is usually given every 3 weeks.
• Your healthcare provider will decide how many treatments you need.
• Your healthcare provider may decrease your dose, temporarily stop or completely stop treatment with Blenrep if you have serious side effects.
• If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form: As injection: 100 mg as a lyophilized powder in a single-dose vial for reconstitution and further dilution.

This medicine is available in fallowing brand namesː

• Blenrep

What side effects can this medication cause?

Common possible side effects of this medicine include:

• keratopathy (corneal epithelium change on eye exam)
• decreased visual acuity
• nausea
• blurred vision
• pyrexia
• infusion-related reactions
• fatigue

Laboratory abnormalities may include:

• platelets decreased
• lymphocytes decreased
• hemoglobin decreased
• neutrophils decreased
• creatinine increased
• gamma-glutamyl transferase increased

What special precautions should I follow?

• Thrombocytopenia may occur. Perform complete blood counts at baseline and during treatment as clinically indicated.
• Infusion-related reactions occurred in 18% of patients treated with Blenrep. Consider withholding and/or reducing the dose based on severity.
• Monitor patients for infusion-related reactions. Interrupt and then reduce the rate or permanently discontinue based on the severity.
• Based on its mechanism of action, Blenrep can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• There are no available data on the use of Blenrep in pregnant women to evaluate for drug-associated risk.
• Advise pregnant women of the potential risk to a fetus.

Can this medicine be used in children?

• The safety and effectiveness of Blenrep in pediatric patients have not been established.

What should I know about storage and disposal of this medication?

• Store vials refrigerated at 36ºF to 46ºF (2ºC to 8ºC).
• Blenrep is a hazardous drug.
• Follow applicable special handling and disposal procedures.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

• Dailymed label info on Belantamab mafodotin
• FDA Belantamab mafodotin

Belantamab mafodotin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Resources

Frequently asked questions

‎